{"product_id":"guerbet-swot-analysis","title":"Guerbet SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Insightful Decisions Backed by Expert Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGuerbet’s strong niche in contrast agents and expanding imaging portfolio position it well amid aging populations and diagnostic demand, but regulatory complexity and competition weigh on margins; our full SWOT unpacks these dynamics, strategic options, and financial implications. Purchase the complete SWOT analysis for a researcher-ready, editable report (Word + Excel) to guide investing, partnerships, or strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket Leadership in Contrast Media\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuerbet holds roughly a 25% share of the global contrast media market, leading MRI and CT segments and supplying over 8,000 hospitals worldwide.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 Guerbet reported €880 million revenue, with contrast media ~70% of sales, and recurring supply contracts covering 60+ countries.\u003c\/p\u003e\n\u003cp\u003eIts strong brand trust among radiologists and procurement teams enables multi-year contracts, supporting stable cash flow and lower revenue volatility across regions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovation in Gadolinium-Based Agents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuerbet’s Elucirem (marketed 2024) drove 2025 macrocyclic contrast sales growth, with Elucirem contributing an estimated €45m of revenue in H1 2025, positioning the company as a leader in high-relaxivity gadolinium agents.\u003c\/p\u003e\n\u003cp\u003eIts higher relaxivity lets clinicians use 25–40% lower doses while keeping image quality, directly addressing gadolinium retention safety concerns and supporting stronger hospital adoption.\u003c\/p\u003e\n\u003cp\u003eOngoing R\u0026amp;D into next-gen diagnostic tools and partnerships—R\u0026amp;D spend rose to €62m in 2024—reinforces Guerbet’s edge versus legacy linear formulations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVertically Integrated Manufacturing Model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGuerbet controls much of its supply chain, from active pharmaceutical ingredient (API) production to final packaging, enabling tighter cost control and quality assurance across operations.\u003c\/p\u003e\n\u003cp\u003eThis vertical integration cut COGS volatility and helped sustain 2025 gross margin near 49% (FY 2025 reported gross margin ~48.8%), shielding EBITDA from supplier shocks and preserving profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Presence in Interventional Radiology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGuerbet has expanded from diagnostic imaging into interventional radiology, selling microcatheters and embolization devices that command higher margins versus contrast agents; interventional sales grew ~18% in 2024, per company filings.\u003c\/p\u003e\n\u003cp\u003eThis segment aligns with the shift to outpatient care—global IR procedure volume rose ~7% CAGR 2019–2024—and supports mix improvement in Guerbet’s 2024 revenue of €820m.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigher-margin devices: microcatheters, embolization\u003c\/li\u003e\n\u003cli\u003eInterventional sales +18% in 2024\u003c\/li\u003e\n\u003cli\u003eCompany revenue €820m (2024)\u003c\/li\u003e\n\u003cli\u003eGlobal IR procedures +7% CAGR 2019–2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distribution and Commercial Footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGuerbet operates in 80+ countries, giving it a broad commercial footprint that generated €883m in 2024 revenue, enabling fast rollout of new contrast agents across mature and emerging markets.\u003c\/p\u003e\n\u003cp\u003eLocal teams handle country-specific regs and reimbursement, cutting time-to-market and improving uptake; for example, 2023 launches saw 20–30% faster adoption in targeted regions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePresence: 80+ countries\u003c\/li\u003e\n\u003cli\u003eRevenue: €883m (2024)\u003c\/li\u003e\n\u003cli\u003eFaster launches: +20–30% adoption\u003c\/li\u003e\n\u003cli\u003eLocalized regulatory\/reimbursement expertise\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGuerbet: €880M 2025 revenue, ~25% global contrast share, Elucirem €45M H1\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGuerbet: ~25% global contrast share; 2025 revenue €880m; contrast ~70% of sales; Elucirem €45m H1 2025; 2024 R\u0026amp;D €62m; gross margin ~48.8%; vertical integration lowers COGS volatility; interventional sales +18% (2024); presence 80+ countries.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 Revenue\u003c\/td\u003e\n\u003ctd\u003e€880m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContrast share\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket share\u003c\/td\u003e\n\u003ctd\u003e~25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eElucirem H1 2025\u003c\/td\u003e\n\u003ctd\u003e€45m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D 2024\u003c\/td\u003e\n\u003ctd\u003e€62m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin 2025\u003c\/td\u003e\n\u003ctd\u003e~48.8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries\u003c\/td\u003e\n\u003ctd\u003e80+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT assessment of Guerbet, outlining its internal strengths and weaknesses alongside external opportunities and threats to clarify strategic priorities and competitive positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise SWOT matrix tailored to Guerbet for rapid strategic alignment and stakeholder-ready summaries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSignificant Financial Leverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpdespite balance-sheet optimization guerbet gbt still carried roughly net debt at fy2024 close largely from prior acquisitions and facility upgrades. this significant leverage narrows firepower for large m or swift strategic pivots. interest expense management is crucial so free cash flow funds r was in than service. what estimate hides: refinancing terms covenants could further constrain flexibility.\u003e\n\u003c\/pdespite\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct Portfolio Concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpa substantial portion of guerbet revenue million comes from a few contrast-agent lines leaving results highly sensitive to regulatory shifts or safety scares in those categories.\u003e\n\u003cpdiversification into digital-health and interventional devices is progressing but adjunct sales remained under million so dependency on core diagnostics persists.\u003e\n\u003c\/pdiversification\u003e\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic Exposure to European Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpguerbet earns about of sales from europe annual report: revenue exposing it to strict government budgets and centralized procurement that drive higher pricing pressure than in the us. tendering reference major markets like france germany cut margins emea operating margin was versus americas showing squeeze. this reliance raises risk eu policy shifts or regional stagnation.\u003e\n\u003c\/pguerbet\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperational Complexity and Restructuring Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGuerbet’s transformation programs have generated notable one-off restructuring charges—€45m in 2023 and €38m in 2024—causing operational friction and EBITDA pressure during implementation.\u003c\/p\u003e\n\u003cp\u003eShifting manufacturing sites and upgrading legacy IT created temporary inefficiencies, tying up working capital and raising OPEX by ~2–3% in affected quarters.\u003c\/p\u003e\n\u003cp\u003eThese complexities have delayed realization of targeted annual cost synergies (initial €30–40m target pushed into 2026).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e€45m restructuring (2023), €38m (2024)\u003c\/li\u003e\n\u003cli\u003eOPEX +2–3% during transitions\u003c\/li\u003e\n\u003cli\u003eCost-synergy target €30–40m delayed to 2026\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Scale Compared to MedTech Giants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpguerbet faces scale limits versus medtech giants like siemens healthineers and ge healthcare whose r spends were about respectively while guerbet was making it hard to match breadth pace.\u003e\n\u003cpthose competitors bundle contrast agents with imaging hardware and services pressuring guerbet specialist model keeping a tech lead needs investment that is large relative to revenue.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 R\u0026amp;D: Guerbet €97m; Siemens €1.4bn; GE $2.3bn\u003c\/li\u003e\n\u003cli\u003e2024 revenue: Guerbet €548m — scale gap limits bundling\u003c\/li\u003e\n\u003cli\u003eHigh capex pressure: innovation costs eat a larger revenue share\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthose\u003e\u003c\/pguerbet\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGuerbet’s €450m debt, R\u0026amp;D and Europe exposure squeeze margins; synergies delayed to 2026\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpguerbet carried net debt at fy2024 close limiting m firepower and raising interest-service pressure on r about of revenue still depends core contrast agents with adjuncts europe sales exposing it to tendering margin squeeze op. vs americas transformation charges delayed synergies raise short-term ebitda risk.\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2023\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e~€450m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue – core agents %\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e€58m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRestructuring charges\u003c\/td\u003e\n\u003ctd\u003e€45m\u003c\/td\u003e\n\u003ctd\u003e€38m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSynergy target\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e€30–40m (delayed to 2026)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/pguerbet\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eGuerbet SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Guerbet SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full report and reflects the same structured, editable content you'll download after checkout. Buy now to unlock the complete, detailed version with strategic insights and actionable findings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752529342841,"sku":"guerbet-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/guerbet-swot-analysis.png?v=1772242036","url":"https:\/\/growthsharematrix.com\/products\/guerbet-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}